(Q38852204)

7 September 2017

1 reference

title

Targeting adipose tissue in the treatment of obesity-associated diabetes (English)

1 reference

7 September 2017

0 references

Christine M Kusminski

series ordinal

1

object named as

Christine M Kusminski

1 reference

7 September 2017

3

Philipp E Scherer

1 reference

7 September 2017

Perry E Bickel

2

1 reference

7 September 2017

3 June 2016

1 reference

Nature Reviews Drug Discovery

7 September 2017

1 reference

7 September 2017

15

1 reference

7 September 2017

9

1 reference

7 September 2017

639-660

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd.2016.75

7 September 2017

0 references

cites work

Mechanisms linking obesity with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Diabetes and apoptosis: lipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose tissue: from lipid storage compartment to endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose tissue remodeling and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Mitochondrial dysfunction in white adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibrosis and adipose tissue dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

What we talk about when we talk about fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The cell biology of fat expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Integrative physiology of human adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Mechanisms and metabolic implications of regional differences among fat depots

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose tissue stem cells meet preadipocyte commitment: going back to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

IFATS collection: Stem cell antigen-1-positive ear mesenchymal stem cells display enhanced adipogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Transcriptional control of adipocyte formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fat and beyond: the diverse biology of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Distinct regulatory mechanisms governing embryonic versus adult adipocyte maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Transcriptional control of preadipocyte determination by Zfp423.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Pdgfrβ+ Mural Preadipocytes Contribute to Adipocyte Hyperplasia Induced by High-Fat-Diet Feeding and Prolonged Cold Exposure in Adult Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Dynamics of fat cell turnover in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipokines in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Severely impaired adipsin expression in genetic and acquired obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Positional cloning of the mouse obese gene and its human homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A novel serum protein similar to C1q, produced exclusively in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

20 years of leptin: leptin at 20: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin: a pivotal regulator of human energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin beyond the lipostat: key component of blood pressure regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin, driver or passenger on the road to insulin sensitivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin: mechanistic insights and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

T-cadherin is critical for adiponectin-mediated cardioprotection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Positive feedback regulation between adiponectin and T-cadherin impacts adiponectin levels in tissue and plasma of male mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin Enhances Cold-Induced Browning of Subcutaneous Adipose Tissue via Promoting M2 Macrophage Proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose tissue mass and location affect circulating adiponectin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin resistance and vascular dysfunction in the hyperlipidemic state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Obesity-associated improvements in metabolic profile through expansion of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Tracking adipogenesis during white adipose tissue development, expansion and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Regional differences in cellular mechanisms of adipose tissue gain with overfeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Transplanted Bone Marrow-Derived Cells Contribute to Human Adipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Regulation of metabolism by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Obesity is associated with macrophage accumulation in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Obesity induces a phenotypic switch in adipose tissue macrophage polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Dietary obesity-associated Hif1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Moderate exercise training provides modest protection against adipose tissue inflammatory gene expression in response to high-fat feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Lifestyle intervention in childhood obesity: changes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A novel role for subcutaneous adipose tissue in exercise-induced improvements in glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

6. Obesity Management for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Benefit-risk assessment of orlistat in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Topiramate-induced weight loss: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Repurposing metformin: an old drug with new tricks in its binding pockets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Regulation of adipocyte formation by GLP-1/GLP-1R signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin regulation of neuroendocrine systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Challenges and opportunities of defining clinical leptin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin dose-dependently decreases atherosclerosis by attenuation of hypercholesterolemia and induction of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin and insulin act on POMC neurons to promote the browning of white fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin reverses declines in satiation in weight-reduced obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

20 years of leptin: role of leptin in energy homeostasis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin-replacement therapy for lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leptin therapy in insulin-deficient type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A new biology of diabetes revealed by leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Development and characterization of high affinity leptins and leptin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Enhanced metabolic flexibility associated with elevated adiponectin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Systemic fate of the adipocyte-derived factor adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Crystal structures of the human adiponectin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin is a negative regulator of bone mineral and bone strength in growing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibroblast growth factor 21: from pharmacology to physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibroblast growth factor 21 corrects obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

FGF21 Regulates Sweet and Alcohol Preference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

FGF21-based pharmacotherapy--potential utility for metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

FGF21 contributes to neuroendocrine control of female reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

FGF21 regulates metabolism and circadian behavior by acting on the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Serum bone morphogenetic protein 7, insulin resistance, and insulin secretion in non-diabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Is interleukin-1β a culprit in macrophage-adipocyte crosstalk in obesity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Interleukin-1β mediates macrophage-induced impairment of insulin signaling in human primary adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

XOMA 052, an anti-IL-1β monoclonal antibody, prevents IL-1β-mediated insulin resistance in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Brown adipose tissue: function and physiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Identification and importance of brown adipose tissue in adult humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Cold-activated brown adipose tissue in healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Functional brown adipose tissue in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Contrast-Enhanced Ultrasound: A Novel Noninvasive, Nonionizing Method for the Detection of Brown Adipose Tissue in Humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The different shades of fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Three years with adult human brown adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Brown adipose tissue activity controls triglyceride clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Regulation of glucose homoeostasis by brown adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Increased brown adipose tissue oxidative capacity in cold-acclimated humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Recruited brown adipose tissue as an antiobesity agent in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Brown fat activation mediates cold-induced thermogenesis in adult humans in response to a mild decrease in ambient temperature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Impact of brown adipose tissue on body fatness and glucose metabolism in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Blunted metabolic responses to cold and insulin stimulation in brown adipose tissue of obese humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Pharmacological strategies for targeting BAT thermogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Cold but not sympathomimetics activates human brown adipose tissue in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Systemic β-adrenergic stimulation of thermogenesis is not accompanied by brown adipose tissue activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Dinitrophenol and obesity: an early twentieth-century regulatory dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Irisin - a myth rather than an exercise-inducible myokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Evidence against a beneficial effect of irisin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

IRF4 is a key thermogenic transcriptional partner of PGC-1α

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Dichotomous effects of VEGF-A on adipose tissue dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

MitoNEET-mediated effects on browning of white adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

PPARs and the complex journey to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

PPARs at the crossroads of lipid signaling and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The protein kinase IKKepsilon regulates energy balance in obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A major role of insulin in promoting obesity-associated adipose tissue inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Leukotriene B4 as a Potential Therapeutic Target for the Treatment of Metabolic Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipocyte-derived endotrophin promotes malignant tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

PDGFRα signaling drives adipose tissue fibrosis by targeting progenitor cell plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

ROCK1 isoform-specific deletion reveals a role for diet-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Immune Cell Toll-like Receptor 4 Mediates the Development of Obesity- and Endotoxemia-Associated Adipose Tissue Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Mitochondrial dysfunction and insulin resistance: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Mitochondria are impaired in the adipocytes of type 2 diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Impaired Mitochondrial Biogenesis in Adipose Tissue in Acquired Obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Enhanced ROS production and oxidative damage in subcutaneous white adipose tissue mitochondria in obese and type 2 diabetes subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: Hope from natural mitochondrial nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Mitochondrial medicine: pharmacological targeting of mitochondria in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

R-alpha-lipoic acid and acetyl-L-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

'Metabolically healthy obesity': origins and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Wound repair and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Adipose-derived mesenchymal stem cells improve glucose homeostasis in high-fat diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Delivery of Adipose-Derived Stem Cells Attenuates Adipose Tissue Inflammation and Insulin Resistance in Obese Mice Through Remodeling Macrophage Phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Intralesional injection of adipose-derived stem cells reduces hypertrophic scarring in a rabbit ear model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Regulation of adipose cell number in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Functional annotation of the human fat cell secretome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Role of Brown Adipose Tissue Thermogenesis in Overfeeding: A Review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Ephedrine activates brown adipose tissue in lean but not obese humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Hepatocyte Toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Glycobiology and cancer: meeting summary and future diections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.75

No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients

31 March 2020

1 reference

12 December 2020

Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase

1 reference

12 December 2020

The distribution of brown adipose tissue in the human

1 reference

12 December 2020

Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies

1 reference

12 December 2020

Understanding the Physiology of FGF21.

1 reference

12 December 2020

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

1 reference

12 December 2020

Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men.

1 reference

12 December 2020

Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults

1 reference

12 December 2020

Adipose-derived Mesenchymal Stem Cells and Their Reparative Potential in Ischemic Heart Disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2016.75

1 reference

7 September 2017

1 reference

PubMed ID

27256476